<DOC>
	<DOCNO>NCT02278393</DOCNO>
	<brief_summary>Investigate safety excessive consumption plant sterol-enriched ferment dairy product 4-week period Japanese healthy adult</brief_summary>
	<brief_title>A Clinical Study Evaluating Safety Plant Sterol-enriched Fermented Dairy Product Japanese Healthy Adults</brief_title>
	<detailed_description />
	<criteria>To check inclusion visit ( V1 ) : II 01 : Male/female subject , age 20 55 year ( bound include ) . II 02 : Subject body mass index ( BMI ) 18.5 kg/m2 ( bound include ) 30 kg/m2 ( bound exclude ) . II 03 : Subject LDLcholesterol plasma level 140 mg/dL ( 3.6 mmol/L ) ( bound exclude ) . II 04 : Subject triglyceride 200 mg/dL ( 2.3 mmol/L ) ( bound include ) . II 05 : Non hypertensive subject define Systolic Blood Pressure ( SBP ) &lt; 140mmHg Diastolic Blood Pressure ( DBP ) &lt; 90 mmHg . II 06 : Subject agree consume supplements/excessive plant sterol plant stanols form study period . II 07 : If childbearing potential , female subject must use comply one follow medically approve method contraception , exclusively : Oral birth control pill ( least 1 full monthly cycle prior study product administration ) ; Intrauterine device ( IUD ) ; Double barrier method ( condom spermicide ) ; OR female subject must postmenopausal least 12 month prior trial entry surgically sterile ( i.e . hysterectomy , bilateral oophorectomy bilateral tubal ligation ) . II 08 : Subject cover social security cover similar system . II 09 : Subject , upon brief content present study , fully understand agree objective ; able personally sign write informed consent . II 10 : Subject give write ( date sign ) inform consent take part study . II 11 : Asian subject originate Japan II12 : Subject able communicate well investigator comply requirement entire study . II13 : Subject fridge home study product storage sufficient capacity . To check randomization visit ( V2 ) : RI 01 : Subject follow dietary recommendation washout period . To check inclusion visit ( V1 ) : IE 01 : Subject experience cardiovascular event ( cardiac infarction , angina attack , surgical endoscopic coronary angioplasty , stroke , arterial disease , etc. ) . IE 02 : Subject suffer serious chronic liver , renal , cardiovascular , respiratory , endocrine metabolic disorder . IE 03 : Subject gastrointestinal disorder ( diarrhoea , constipation , irritable bowel syndrome ) use laxative . IE 04 : Subject diabetes Type I Type II Fasting Blood Sugar test ( FBS ) &gt; 125 mg/dL screen visit . IE 05 : Subject active liver disease hepatic dysfunction define elevation liver enzyme : [ alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gamma glutamyl transferase ( GGT ) &gt; 3X upper limit normal ( ULN ) . IE 06 : Subject unexplained serum creatine phosphokinase ( CPK ) &gt; 2X upper limit normal ( ULN ) . Subject reason CPK elevation may continue inclusion process measurement repeat prior randomization ; repeat CPK &gt; 2X ULN exclusionary . IE 07 : Subject weight change ( variation &gt; 5 % ) within 6 month least prior inclusion . IE 08 : Subject take hypocholesterolemic drug product ( statin , ezetimibe , sequesterants , niacin , nicotinates , probucol , omega3 fatty acid ( EPADHA , ALAâ€¦ ) , fibrates ) . IE 09 : Subjects stop hypocholesterolemic drug product less 3 month IE 10 : Subject know lactose intolerance . IE 11 : Subject know allergy hypersensitivity plant sterols component study product ( milk protein example ) . IE 12 : Subjects sitosterolemia . IE 13 : Subject surgery intervention require general anaesthesia precede 4 week , plan one course study . IE 14 : Subject receiving ( currently 4 last week ) systemic treatment topical treatment likely interfere evaluation study parameter . IE 15 : Subject involved clinical study within precede month exclusion period another clinical study . IE 16 Subject blood sample 200 mL take ( e.g. , donate blood ) within 1 month , 400 mL within 3 month start present study . IE 17 : Subject heavy alcohol intake ( &gt; 60 g/day ) . IE 18 : Subject take treatment anorexia , weight loss , form treatment likely interfere metabolism dietary habit ( e.g . hypolipemic , hypoglycaemic treatment ) . IE 19 : For female subject : pregnant woman woman plan become pregnant study ; breastfeed woman . IE 20 : For female subject : subject likely change contraceptive method hormone replacement therapy study . IE 21 : Subject situation , investigator 's opinion could interfere optimal participation present study ( e.g . product consumer ) could constitute special risk subject . IE 22 : Subject susceptible comply dietary qualitative restriction study period . IE 23 Vulnerable subject defined individual whose willingness volunteer clinical trial may unduly influenced expectation , whether justify , benefit associate participation , retaliatory response senior member hierarchy case refusal participate . Examples member group hierarchical structure , medical , pharmacy , dental nursing student , subordinate hospital laboratory personnel , employee pharmaceutical industry , member arm force , person keep detention . IE 24 : Subject expect living home current participate subject concomitantly receive study product .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Japanese healthy volunteer</keyword>
	<keyword>High LDL-C</keyword>
	<keyword>dairy drink</keyword>
	<keyword>phytosterols</keyword>
</DOC>